The Dysbindin Gene (DTNBP1) Is Associated with Methamphetamine Psychosis

Makiko Kishimoto, Hiroshi Ujike, Yasuko Motohashi, Yuji Tanaka, Yuko Okahisa, Tatsuya Kotaka, Mutsuo Harano, Toshiya Inada, Mitsuhiko Yamada, Tokutaro Komiyama, Toru Hori, Yoshimoto Sekine, Nakao Iwata, Ichiro Sora, Masaomi Iyo, Norio Ozaki, Shigetoshi Kuroda

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Background: The dysbindin (DTNBP1 [dystrobrevin-binding protein 1]) gene has repeatedly been shown to be associated with schizophrenia across diverse populations. One study also showed that risk haplotypes were shared with a bipolar disorder subgroup with psychotic episodes, but not with all cases. DTNBP1 may confer susceptibility to psychotic symptoms in various psychiatric disorders besides schizophrenia. Methods: Methamphetamine psychosis, the psychotic symptoms of which are close to those observed in schizophrenia, was investigated through a case (n = 197)-control (n = 243) association analyses of DTNBP1. Results: DTNBP1 showed significant associations with methamphetamine psychosis at polymorphisms of P1635 (rs3213207, p = .00003) and SNPA (rs2619538, p = .049) and the three-locus haplotype of P1655 (rs2619539)-P1635-SNPA (permutation p = .0005). The C-A-A haplotype, which was identical to the protective haplotype previously reported for schizophrenia and psychotic bipolar disorders, was a protective factor (p = .0013, odds ratio [OR] = .62, 95% confidence interval [CI] .51-.77) for methamphetamine psychosis. The C-G-T haplotype was a risk for methamphetamine psychosis (p = .0012, OR = 14.9, 95% CI 3.5-64.2). Conclusions: Our genetic evidence suggests that DTNBP1 is involved in psychotic liability not only for schizophrenia but also for other psychotic disorders, including substance-induced psychosis.

Original languageEnglish
Pages (from-to)191-196
Number of pages6
JournalBiological Psychiatry
Volume63
Issue number2
DOIs
Publication statusPublished - Jan 15 2008

Fingerprint

Methamphetamine
Psychotic Disorders
Haplotypes
Schizophrenia
Genes
Bipolar Disorder
Substance-Induced Psychoses
Odds Ratio
Confidence Intervals
Psychiatry
Carrier Proteins
Population

Keywords

  • Akt1
  • DTNBP1
  • dysbindin
  • methamphetamine psychosis
  • substance dependence

ASJC Scopus subject areas

  • Biological Psychiatry

Cite this

Kishimoto, M., Ujike, H., Motohashi, Y., Tanaka, Y., Okahisa, Y., Kotaka, T., ... Kuroda, S. (2008). The Dysbindin Gene (DTNBP1) Is Associated with Methamphetamine Psychosis. Biological Psychiatry, 63(2), 191-196. https://doi.org/10.1016/j.biopsych.2007.03.019

The Dysbindin Gene (DTNBP1) Is Associated with Methamphetamine Psychosis. / Kishimoto, Makiko; Ujike, Hiroshi; Motohashi, Yasuko; Tanaka, Yuji; Okahisa, Yuko; Kotaka, Tatsuya; Harano, Mutsuo; Inada, Toshiya; Yamada, Mitsuhiko; Komiyama, Tokutaro; Hori, Toru; Sekine, Yoshimoto; Iwata, Nakao; Sora, Ichiro; Iyo, Masaomi; Ozaki, Norio; Kuroda, Shigetoshi.

In: Biological Psychiatry, Vol. 63, No. 2, 15.01.2008, p. 191-196.

Research output: Contribution to journalArticle

Kishimoto, M, Ujike, H, Motohashi, Y, Tanaka, Y, Okahisa, Y, Kotaka, T, Harano, M, Inada, T, Yamada, M, Komiyama, T, Hori, T, Sekine, Y, Iwata, N, Sora, I, Iyo, M, Ozaki, N & Kuroda, S 2008, 'The Dysbindin Gene (DTNBP1) Is Associated with Methamphetamine Psychosis', Biological Psychiatry, vol. 63, no. 2, pp. 191-196. https://doi.org/10.1016/j.biopsych.2007.03.019
Kishimoto, Makiko ; Ujike, Hiroshi ; Motohashi, Yasuko ; Tanaka, Yuji ; Okahisa, Yuko ; Kotaka, Tatsuya ; Harano, Mutsuo ; Inada, Toshiya ; Yamada, Mitsuhiko ; Komiyama, Tokutaro ; Hori, Toru ; Sekine, Yoshimoto ; Iwata, Nakao ; Sora, Ichiro ; Iyo, Masaomi ; Ozaki, Norio ; Kuroda, Shigetoshi. / The Dysbindin Gene (DTNBP1) Is Associated with Methamphetamine Psychosis. In: Biological Psychiatry. 2008 ; Vol. 63, No. 2. pp. 191-196.
@article{70470e1f687a4066a9e41f363be6e0a8,
title = "The Dysbindin Gene (DTNBP1) Is Associated with Methamphetamine Psychosis",
abstract = "Background: The dysbindin (DTNBP1 [dystrobrevin-binding protein 1]) gene has repeatedly been shown to be associated with schizophrenia across diverse populations. One study also showed that risk haplotypes were shared with a bipolar disorder subgroup with psychotic episodes, but not with all cases. DTNBP1 may confer susceptibility to psychotic symptoms in various psychiatric disorders besides schizophrenia. Methods: Methamphetamine psychosis, the psychotic symptoms of which are close to those observed in schizophrenia, was investigated through a case (n = 197)-control (n = 243) association analyses of DTNBP1. Results: DTNBP1 showed significant associations with methamphetamine psychosis at polymorphisms of P1635 (rs3213207, p = .00003) and SNPA (rs2619538, p = .049) and the three-locus haplotype of P1655 (rs2619539)-P1635-SNPA (permutation p = .0005). The C-A-A haplotype, which was identical to the protective haplotype previously reported for schizophrenia and psychotic bipolar disorders, was a protective factor (p = .0013, odds ratio [OR] = .62, 95{\%} confidence interval [CI] .51-.77) for methamphetamine psychosis. The C-G-T haplotype was a risk for methamphetamine psychosis (p = .0012, OR = 14.9, 95{\%} CI 3.5-64.2). Conclusions: Our genetic evidence suggests that DTNBP1 is involved in psychotic liability not only for schizophrenia but also for other psychotic disorders, including substance-induced psychosis.",
keywords = "Akt1, DTNBP1, dysbindin, methamphetamine psychosis, substance dependence",
author = "Makiko Kishimoto and Hiroshi Ujike and Yasuko Motohashi and Yuji Tanaka and Yuko Okahisa and Tatsuya Kotaka and Mutsuo Harano and Toshiya Inada and Mitsuhiko Yamada and Tokutaro Komiyama and Toru Hori and Yoshimoto Sekine and Nakao Iwata and Ichiro Sora and Masaomi Iyo and Norio Ozaki and Shigetoshi Kuroda",
year = "2008",
month = "1",
day = "15",
doi = "10.1016/j.biopsych.2007.03.019",
language = "English",
volume = "63",
pages = "191--196",
journal = "Biological Psychiatry",
issn = "0006-3223",
publisher = "Elsevier USA",
number = "2",

}

TY - JOUR

T1 - The Dysbindin Gene (DTNBP1) Is Associated with Methamphetamine Psychosis

AU - Kishimoto, Makiko

AU - Ujike, Hiroshi

AU - Motohashi, Yasuko

AU - Tanaka, Yuji

AU - Okahisa, Yuko

AU - Kotaka, Tatsuya

AU - Harano, Mutsuo

AU - Inada, Toshiya

AU - Yamada, Mitsuhiko

AU - Komiyama, Tokutaro

AU - Hori, Toru

AU - Sekine, Yoshimoto

AU - Iwata, Nakao

AU - Sora, Ichiro

AU - Iyo, Masaomi

AU - Ozaki, Norio

AU - Kuroda, Shigetoshi

PY - 2008/1/15

Y1 - 2008/1/15

N2 - Background: The dysbindin (DTNBP1 [dystrobrevin-binding protein 1]) gene has repeatedly been shown to be associated with schizophrenia across diverse populations. One study also showed that risk haplotypes were shared with a bipolar disorder subgroup with psychotic episodes, but not with all cases. DTNBP1 may confer susceptibility to psychotic symptoms in various psychiatric disorders besides schizophrenia. Methods: Methamphetamine psychosis, the psychotic symptoms of which are close to those observed in schizophrenia, was investigated through a case (n = 197)-control (n = 243) association analyses of DTNBP1. Results: DTNBP1 showed significant associations with methamphetamine psychosis at polymorphisms of P1635 (rs3213207, p = .00003) and SNPA (rs2619538, p = .049) and the three-locus haplotype of P1655 (rs2619539)-P1635-SNPA (permutation p = .0005). The C-A-A haplotype, which was identical to the protective haplotype previously reported for schizophrenia and psychotic bipolar disorders, was a protective factor (p = .0013, odds ratio [OR] = .62, 95% confidence interval [CI] .51-.77) for methamphetamine psychosis. The C-G-T haplotype was a risk for methamphetamine psychosis (p = .0012, OR = 14.9, 95% CI 3.5-64.2). Conclusions: Our genetic evidence suggests that DTNBP1 is involved in psychotic liability not only for schizophrenia but also for other psychotic disorders, including substance-induced psychosis.

AB - Background: The dysbindin (DTNBP1 [dystrobrevin-binding protein 1]) gene has repeatedly been shown to be associated with schizophrenia across diverse populations. One study also showed that risk haplotypes were shared with a bipolar disorder subgroup with psychotic episodes, but not with all cases. DTNBP1 may confer susceptibility to psychotic symptoms in various psychiatric disorders besides schizophrenia. Methods: Methamphetamine psychosis, the psychotic symptoms of which are close to those observed in schizophrenia, was investigated through a case (n = 197)-control (n = 243) association analyses of DTNBP1. Results: DTNBP1 showed significant associations with methamphetamine psychosis at polymorphisms of P1635 (rs3213207, p = .00003) and SNPA (rs2619538, p = .049) and the three-locus haplotype of P1655 (rs2619539)-P1635-SNPA (permutation p = .0005). The C-A-A haplotype, which was identical to the protective haplotype previously reported for schizophrenia and psychotic bipolar disorders, was a protective factor (p = .0013, odds ratio [OR] = .62, 95% confidence interval [CI] .51-.77) for methamphetamine psychosis. The C-G-T haplotype was a risk for methamphetamine psychosis (p = .0012, OR = 14.9, 95% CI 3.5-64.2). Conclusions: Our genetic evidence suggests that DTNBP1 is involved in psychotic liability not only for schizophrenia but also for other psychotic disorders, including substance-induced psychosis.

KW - Akt1

KW - DTNBP1

KW - dysbindin

KW - methamphetamine psychosis

KW - substance dependence

UR - http://www.scopus.com/inward/record.url?scp=37349024301&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37349024301&partnerID=8YFLogxK

U2 - 10.1016/j.biopsych.2007.03.019

DO - 10.1016/j.biopsych.2007.03.019

M3 - Article

C2 - 17555717

AN - SCOPUS:37349024301

VL - 63

SP - 191

EP - 196

JO - Biological Psychiatry

JF - Biological Psychiatry

SN - 0006-3223

IS - 2

ER -